ライフサイエンスコーパス: SCFA

1 SCFA accounted for 63+/-4% (mean+/-SEM) of carbon units

2 SCFA also suppressed effector T cell induction in the CL

3 SCFA are protective in various animal models of inflamma

4 SCFA influence host health as energy sources and via mul

5 SCFA levels in anaerobic supernatants and bronchoalveola

6 SCFA levels were higher in BAL samples of adults than in

7 SCFA production represents an adaptive process to conser

8 SCFA receptors, termed FFA2 and FFA3, are expressed in d

9 SCFA-induced IL-8 secretion was monitored by ELISA.

10 SCFA/HCO3(-) exchange also appears to be present in the

11 SCFAs activate GPR41 and GPR43 on intestinal epithelial

12 SCFAs activated intestinal epithelial cells to produce c

13 SCFAs also downregulate expression of enhancer of zeste

14 SCFAs and metabolite receptors thus explain health benef

15 SCFAs are end products of fermentation by the gut microb

16 SCFAs binding to GPR43 on colonic epithelial cells stimu

17 SCFAs binding to the 'metabolite-sensing' receptors GPR4

18 SCFAs differentially affected EBV and KSHV reactivation.

19 SCFAs generate IL-10(+) regulatory T cells, which may pr

20 SCFAs induce embryonic globin gene expression in eFLCS,

21 SCFAs induced a dose-dependent and pertussis toxin-sensi

22 SCFAs inhibit class-1/2 histone deacetylases (HDACs) and

23 SCFAs inhibited IFN-gamma and IL-17A production in perip

24 SCFAs, the predominant anions of colonic fluid derived f

25 lonyl-ACP is thus converted to acetyl-ACP, a SCFA precursor).

26 mal HIV-1 forms in the viral life cycle in a SCFA-rich gut environment.

27 ated N-acetyl-D-mannosamine (Bu(4)ManNAc), a SCFA-hexosamine cancer drug candidate with activity mani

28 Propionate, a SCFA shown to induce vasodilation ex vivo, produces an a

29 Upon treatment with acetate SCFA or FFAR2- and FFAR3-specific synthetic agonists, hu

30 s, in particular the short-chain fatty acid (SCFA) acetate, are believed to be involved in these proc

31 ctrophoresis (DGGE), short-chain fatty acid (SCFA) and ammonium analyses were carried out for monitor

32 iota composition and short-chain fatty acid (SCFA) concentrations in parallel with host immunometabol

33 um butyrate (NaB), a short-chain fatty acid (SCFA) histone deacetylase (HDAC) inhibitor.

34 ency (P = 0.02), and short-chain fatty acid (SCFA) producer Lachnospira [false-discovery rate (FDR)-c

35 , allowing increased short chain fatty acid (SCFA) production.

36 licate the mammalian short-chain fatty acid (SCFA) receptors, FFAR2 and FFAR3- in colitis, arthritis

37 Butyrate is a short chain fatty acid (SCFA) that bypasses the LCFA transporters of mitochondri

38 te (NaBu), a form of short-chain fatty acid (SCFA), acts classically as a potent anti-angiogenic agen

39 found that in mice a short-chain fatty acid (SCFA), butyrate, produced by commensal microorganisms du

40 e in the levels of a short chain fatty acid (SCFA), butyrate.

41 tyrate (4 mmol/L), a short chain fatty acid (SCFA), plus [2-(13)C] glucose (10 mmol/L) in either noni

42 ponses engendered by short chain fatty acid (SCFA)-hexosamine hybrid molecules, a class of compounds

43 d proteins produces short-chain fatty acids (SCFA) and a range of other metabolites including those f

44 Short chain fatty acids (SCFA) are metabolites of intestinal bacteria resulting f

45 Short-chain fatty acids (SCFA) are the major anion in stool and are synthesized f

46 roperties of faecal short-chain fatty acids (SCFA) as diagnostic biomarkers for IBS.

47 (Cys122Gln) more straight-chain fatty acids (SCFA) than the corresponding wild-type strain.

48 Short-chain fatty acids (SCFA) were measured by HPLC.

49 emistry, intestinal short chain fatty acids (SCFA), and liver glycogen of triplicate groups of 20 red

50 Short-chain fatty acids (SCFA), formed by microbial fermentation, are believed to

51 We determined that short-chain fatty acids (SCFA), microbiota-derived bacterial fermentation product

52 Two other short-chain fatty acids (SCFA), propionate and butyrate, present in high concentr

53 carbohydrates into short-chain fatty acids (SCFA).

54 R43), for which the short-chain fatty acids (SCFAs) acetate and propionate are agonist, have emerged

55 sensitivity to the short chain fatty acids (SCFAs) acetate and propionate.

56 microbiota-derived short-chain fatty acids (SCFAs) after allogeneic bone marrow transplant (allo-BMT

57 lic metabolites and short chain fatty acids (SCFAs) and compare relative antioxidant capacities follo

58 Short-chain fatty acids (SCFAs) and dimethyl sulfoxide (DMSO) induce adult erythr

59 rated fiber-derived short-chain fatty acids (SCFAs) and free fatty acid receptors including GPR43 are

60 Because short-chain fatty acids (SCFAs) and heat shock proteins (hsps) confer protection

61 KEY POINTS: The short-chain fatty acids (SCFAs) are bacterial metabolites produced during the col

62 The short-chain fatty acids (SCFAs) are bacterial metabolites produced during the col

63 Short-chain fatty acids (SCFAs) are fermentation end products produced by the int

64 Short-chain fatty acids (SCFAs) are major products of gut microbial fermentation

65 Short-chain fatty acids (SCFAs) are physiological regulators of growth and differ

66 Short chain fatty acids (SCFAs) are produced in the gut by bacterial fermentation

67 Short-chain fatty acids (SCFAs) are the main products of dietary fiber fermentati

68 duce five different short-chain fatty acids (SCFAs) as metabolic by-products.

69 lprotectin, and the short-chain fatty acids (SCFAs) butyrate and propionate were determined in childr

70 tory cells, and the short chain fatty acids (SCFAs) butyrate, propionate and acetate also induce simi

71 ecal microbiota and short-chain fatty acids (SCFAs) in patients starting 14-d of enteral feeding and

72 g in high levels of short chain fatty acids (SCFAs) in the cecal material and enhancement of cell den

73 effects of luminal short-chain fatty acids (SCFAs) in the foregut are unknown.

74 t dietary fiber and short chain fatty acids (SCFAs) induced the expression of the vitamin A-convertin

75 Luminal short-chain fatty acids (SCFAs) influence gut physiological function via SCFA rec

76 the form of various short-chain fatty acids (SCFAs) known to be endogenously produced by normal micro

77 dietary fiber into short chain fatty acids (SCFAs) known to be important for human health.

78 Short-chain fatty acids (SCFAs) of 2 to 6 carbons in length induce gamma globin e

79 e concentrations of short-chain fatty acids (SCFAs) present in the ileum and cecum of streptomycin-tr

80 Short-chain fatty acids (SCFAs) promoted TPH1 transcription in BON cells (human E

81 nsals, which supply short chain fatty acids (SCFAs) such as acetate, also exhibit altered insulin sig

82 mensal bacteria are short-chain fatty acids (SCFAs) that derive from fermentation of dietary fibre.

83 d as a receptor for short-chain fatty acids (SCFAs) that include acetate and propionate.

84 , anaerobes produce short-chain fatty acids (SCFAs) that modulate immune and inflammatory processes.

85 nstrate that excess short-chain fatty acids (SCFAs) trigger replicative cells to cease growth and act

86 etermined by ELISA; short-chain fatty acids (SCFAs) were measured in stool samples by using gas chrom

87 icrobiota producing short-chain fatty acids (SCFAs) with the ability to prevent inflammation.

88 The short-chain fatty acids (SCFAs), acetate, propionate and butyrate, are bacterial

89 ABSTRACT: The short-chain fatty acids (SCFAs), acetate, propionate and butyrate, are bacterial

90 ia, total bacteria, short-chain fatty acids (SCFAs), and fecal pH in women with low iron status (plas

91 acterially produced short-chain fatty acids (SCFAs), as a modulator of microbiota-host interaction.

92 valproic acid, both short-chain fatty acids (SCFAs), dramatically increase cellular sensitivity to es

93 ch generate only straight-chain fatty acids (SCFAs), FabH has a substrate preference for acetyl-CoA.

94 butyrate and other short-chain fatty acids (SCFAs), induce regulatory T cells (Tregs).

95 Short-chain fatty acids (SCFAs), metabolites produced through the microbial ferme

96 We report that short-chain fatty acids (SCFAs), produced by gut microbiota as fermentation produ

97 c-treated mice with short-chain fatty acids (SCFAs), products of microbial metabolism, restores IGF-1

98 uch as vitamins and short-chain fatty acids (SCFAs), regulate Treg generation, trafficking, and funct

99 Microbiota-produced short-chain fatty acids (SCFAs), substrates in the colonic ketone body pathway, a

100 Short-chain fatty acids (SCFAs), such as butyrate, produced through anaerobic mic

101 tential mechanisms, short chain fatty acids (SCFAs), the byproducts of microbial fermentation of diet

102 Short-chain fatty acids (SCFAs), the most abundant microbial metabolites in the i

103 he colon to produce short-chain fatty acids (SCFAs), which are proposed to have systemic anti-inflamm

104 ible" prebiotics to short-chain fatty acids (SCFAs), which in turn modulate the release of gut hormon

105 icrobially-produced short-chain fatty acids (SCFAs).

106 bility of producing short-chain fatty acids (SCFAs).

107 ) when activated by short-chain fatty acids (SCFAs).

108 kidney, responds to short chain fatty acids (SCFAs).

109 receptors for short chain free fatty acids (SCFAs).

110 Short-chain fatty acids (SCFAs; butyrate and propionate) up-regulate embryonic/fe

111 ntified the fraction of colonic administered SCFAs that could be recovered in the systemic circulatio

112 Orally administered SCFAs induced effector (Th1 and Th17) and regulatory T c

113 KSHV was reactivated by all SCFAs that are HDAC inhibitors, including phenylbutyrate

114 The contribution of an SCFA receptor, free fatty acid receptor (FFA)3, to the e

115 d this ratio; V(TCA)/V(PAL) = 12:1 due to an SCFA-induced increase in V(TCA) of 43% (p < 0.05).

116 pocket to regulate constitutive activity and SCFA potency.

117 obiota with the host metabolic functions and SCFA levels.

118 FFA1), which binds long-chain FA (LCFA), and SCFA receptors FFA2 and FFA3 were immunolocalised to duo

119 composition of SCFA-producing microbiota and SCFA production in the small intestines.

120 FARs) for long-chain fatty acids (LCFAs) and SCFAs are expressed in enteroendocrine cells.

121 esulted in different phenolic metabolite and SCFAs profiles in each colonic segment, with important h

122 ], or p300/CBP-associated factor [PCAF]) and SCFAs, were performed.

123 protein-coupled receptor 41 (Gpr41), another SCFA receptor, are expressed in smooth muscle cells of s

124 phery was potentiated by propionate, another SCFA of microbial origin capable of histone deacetylase

125 Valproic acid (VPA), another SCFA and an HDAC inhibitor, induces the lytic cycle of K

126 Because SCFA bypass LCFA transport into mitochondria, during LAD

127 er organisms which produce a mixture of both SCFAs and branched-chain fatty acids (BCFAs), FabH has b

128 ation of FFA1 by LCFA and presumably FFA3 by SCFA increased DBS via GLP-2 release, whereas FFA2 activ

129 obstruction, which was, in turn, induced by SCFA-induced inflammation in the ureteropelvic junction

130 d p38), were not differentially activated by SCFAs in eFLCs; but increased bulk histone (H3) acetylat

131 erts anti-inflammatory activity, mediated by SCFAs production from its dietary fiber, by reducing the

132 ontrol mice; signaling pathways regulated by SCFAs were identified using immunohistochemical, enzyme-

133 studied regulation of the immune response by SCFAs and their receptors in the intestines of mice.

134 elivery capsules and plasma levels of (13) C-SCFAs (13) C-glucose, (13) C-cholesterol and (13) C-fatt

135 In B cells, SCFAs increase acetyl-CoA and regulate metabolic sensors

136 ng apical membrane Na-H, SCFA-HCO(3), and Cl-SCFA exchanges.

137 osmotically mediated diarrhea; in contrast, SCFA are absorbed by colonic epithelial cells and stimul

138 ty to show that LCFAs consistently decreased SCFAs in the gut and exacerbated disease by expanding pa

139 These results demonstrate SCFA-AhR ligand interactions in YAMC and Caco-2 cells wh

140 Animal research suggests that colon-derived SCFAs modulate feeding behavior via central mechanisms.

141 Dietary SCFA supplementation prevented and reversed high-fat die

142 Here we show that dietary SCFAs induce a peroxisome proliferator-activated recepto

143 ix and match" strategy showed that different SCFA (n-butyrate and acetate) appended to the same core

144 The different SCFAs stimulate lytic gene expression of Kaposi's sarcom

145 tial to that promoter's up-regulation during SCFA-mediated induction of adult erythroid differentiati

146 vestigated, in depth, the impact of elevated SCFA levels on T cells and tissue inflammation in mice.

147 pathological effects of chronically elevated SCFAs.

148 Medium roasted hgf-NDSCG produced elevated SCFAs (61:22:17, acetate, propionate and butyrate) after

149 3 and serum levels of acetate, an endogenous SCFA, are increased with a high-fat diet (HFD).

150 a murine model of definitive erythropoiesis, SCFAs increased embryonic beta-type globin gene expressi

151 ntiation of cells treated with either excess SCFAs or the fatty acid biosynthesis inhibitors ceruleni

152 The study indicated that faecal SCFA could be a non-invasive, valid and reliable biomark

153 phy-mass spectrometry revealed higher faecal SCFAs, including butyrate, propionate, valerate, isovale

154 regions, and the short-chain saturated FAs (SCFA; C4:0-C11:0) - of the lowland ones.

155 Alternatively, dietary short-chain FAs (SCFAs) expanded gut T regulatory (Treg) cells by suppres

156 overgrowth, which generate short-chain FAs (SCFAs), have been implicated in the generation of functi

157 cal microbiota composition, plasma and fecal SCFA, energy expenditure and substrate oxidation, body c

158 al inflammation, low concentrations of fecal SCFAs, and high systemic inflammation are significantly

159 ctate (P < 0.001) but had no effect on fecal SCFAs and total bacteria.

160 hea had higher concentrations of total fecal SCFAs (P = 0.044), acetate (P = 0.029), and butyrate (P

161 of C rodentium infection on control mice fed SCFAs and/or given injections of antibodies that delay t

162 , and fermentability by the human gut flora, SCFAs production, nitric oxide and cytokine expression o

163 Stool samples were analysed for SCFA (acetic acid, propionic acid, butyric acid, isobuty

164 rapeutic end point (control of invasion) for SCFA-hexosamine hybrid molecules, define relative contri

165 Apc gene and that were either wild-type for SCFA metabolism, or deficient, due to homozygous deletio

166 t fluorescence in situ hybridization and for SCFAs by using gas-liquid chromatography.

167 The potency for SCFAs on FFA2 is low, in the high micromolar to millimol

168 Gel-shift analyses of binding activity from SCFA-induced MEL cell nuclear extracts showed in vitro b

169 Furthermore, SCFAs ameliorated the effects of hypoxia in kidney epith

170 dent process involving apical membrane Na-H, SCFA-HCO(3), and Cl-SCFA exchanges.

171 These results highlight SCFAs and their receptors as potential targets for the t

172 However, SCFA or dietary fiber intake restores this immune defici

173 However, SCFA oxidation did not significantly reduce palmitate tr

174 However, SCFA receptor (GPR41 or GPR43) deficiency did not affect

175 However, SCFAs can also induce Th1 and Th17 cells upon immunologi

176 Based on these findings, we examined if SCFAs promote epithelial barrier through IL-10RA-depende

177 cases also yielded corresponding changes in SCFA potency.

178 ed bulk histone (H3) acetylation was seen in SCFA-treated eFLCs.

179 drogenase, which catalyzes the first step in SCFA B-oxidation.

180 C2 and C3 resulted from broad differences in SCFAs potency at the mouse orthologs.

181 significantly impaired by either inhibiting SCFA production or genetic ablation of GPR43.

182 In the PG treatments, intestinal SCFA significantly decreased while plasma glucose, chole

183 uman colon by measurement of (13) C-labelled SCFA concentrations in blood.

184 lysis similar to that of endogenous ligands (SCFAs).

185 whereas diarrhea, high calprotectin, and low SCFA production related to death indirectly via their mo

186 Mice with low SCFA production due to reduced dietary fiber consumption

187 further supports the hypothesis that luminal SCFA in the foregut may contribute towards the generatio

188 We studied the mechanisms by which luminal SCFA perfusion affects duodenal HCO3(-) secretion (DBS),

189 Although luminal SCFAs evoke electrogenic anion secretion and smooth musc

190 nts of host epigenetic regulatory machinery, SCFAs increase histone acetylation and decrease repressi

191 Microbial populations, including the main SCFA-butyrate producers in the colon, were not altered i

192 We observed that therapy with the three main SCFAs (acetate, propionate, and butyrate) improved renal

193 Oral administration of all major SCFAs, such as acetate, propionate, and butyrate, induce

194 ntrol region (LCR) were essential to maximal SCFA-mediated induction of expression from these constru

195 s modest positive effects on gut microbiota, SCFAs, effector memory T cells, and the acute innate imm

196 uch as VSL#3 can modulate the gut microbiota-SCFA-hormone axis.

197 Moreover, SCFAs inhibited histone deacetylase activity and modulat

198 f dietary fiber can alter the composition of SCFA-producing microbiota and SCFA production in the sma

199 Colonic infusions of SCFA mixtures, in concentrations and ratios reached afte

200 Inhibition of SCFA synthesis by antibiotics and administration of PEG,

201 The presence of SCFA sensing in the duodenum with GLP-2 and 5-HT signals

202 In contrast, increased production of SCFA as a result of providing starch that is relatively

203 populations and shifts in the production of SCFA.

204 llow future evaluation and quantification of SCFA production from (13) C-labelled fibres in the human

205 Therefore, we evaluated the role of SCFA in an AKI model in which the inflammatory process h

206 ting previous results where a single type of SCFA elicited distinct responses.

207 A detailed understanding of SCFA metabolism by the gut microbiota is necessary to un

208 findings support exogenous administration of SCFAs as a potential treatment strategy for uveitis thro

209 present study, the systemic availability of SCFAs and their incorporation into biologically relevant

210 Further, a combination of SCFAs found in the distal ileum restored invasion gene e

211 st that the concentration and composition of SCFAs in the distal ileum provide a signal for productiv

212 etabolites, the intestinal concentrations of SCFAs and biogenic amines decreased with the dietary pro

213 erobes produced millimolar concentrations of SCFAs, including acetic, propionic, and butyric acids.

214 This review examines the effect of SCFAs, prebiotics, and pre- and probiotic combinations (

215 tical mediators of the beneficial effects of SCFAs on the metabolic syndrome, with clearly distinct a

216 red eligible if they examined the effects of SCFAs, prebiotics, or synbiotics; were delivered orally,

217 This B cell-helping function of SCFAs is detected from the intestines to systemic tissue

218 We detect significantly higher levels of SCFAs in the saliva of patients with severe periodontal

219 ether elimination of efficient metabolism of SCFAs affected apoptosis in the gastrointestinal mucosa

220 Therefore, the metabolism of SCFAs by the gastrointestinal mucosa plays a role in mod

221 demonstrating that uptake and metabolism of SCFAs in the gastrointestinal tract can be a significant

222 ly impacts in vitro fermentation profiles of SCFAs from fibers with different chemical structures.

223 producing different amounts and profiles of SCFAs from the same carbohydrate substrates.

224 Properties of SCFAs in addition to their effects on chromatin are like

225 Us leading to different levels and ratios of SCFAs.

226 Alterations in the amount of only one SCFA, butyrate, were observed only in the intestinal tis

227 murine erythroleukemia (MEL) cells, but only SCFAs concurrently up-regulate expression from the endog

228 to underpin effective strategies to optimize SCFA supply to the host.

229 o significant changes in fecal microbiota or SCFAs were observed during enteral feeding, stark altera

230 Oral SCFA administration attenuated uveitis severity in a mou

231 to the onset of uveitis were blunted by oral SCFA administration.

232 Other SCFAs, including the poorly metabolized isobutyate, also

233 operfused myocardium preferentially oxidized SCFA over endogenous LCFA.

234 Because of the seemingly paradoxical SCFA activities in regulating T cells, we investigated,

235 In parallel, SCFAs control gene expression to express molecules neces

236 coupling of GPR43 to Gq signaling pathways, SCFAs raised cytosolic Ca2+ in L cells in primary cultur

237 e any differences in fecal or fasting plasma SCFA concentrations or in systemic concentrations of gut

238 The YL/ecFabH mutant produces predominantly SCFAs (86%).

239 rt that one of the main bacterially produced SCFAs, propionate, activates ileal mucosal free fatty ac

240 omparable, while the capability of producing SCFAs and butyric acid was superior to the control rice

241 Pulmonary SCFAs correlated with increased oral anaerobes, such as

242 ice lacking ffar2 or ffar3 exhibited reduced SCFA-triggered GLP-1 secretion in vitro and in vivo and

243 c administration of physiologically relevant SCFA mixtures on human substrate and energy metabolism.

244 Increase in serum SCFAs was associated with increased TB susceptibility.

245 Similarly, SCFA-induced reduction of hepatic steatosis was absent i

246 Of factors that interact at the CACCC site, SCFA-mediated acetylation is implicated in SP1 and EKLF,

247 We conclude that SCFAs produced by the gut microbiota modulate blood pres

248 Thus, we demonstrate that SCFAs improve organ function and viability after an inju

249 epithelial cells (IECs), we discovered that SCFAs, particularly butyrate, enhanced IEC barrier forma

250 We show here that SCFAs trigger secretion of the incretin hormone glucagon

251 This study illustrates that SCFAs contribute to excessive production of IL-8 in CF a

252 Our findings indicate that SCFAs may be used therapeutically as cheap and selective

253 Collectively, we show that SCFAs act via FFAR2/3 to modulate human monocyte inflamm

254 In vitro analyses showed that SCFAs modulated the inflammatory process, decreasing the

255 ew findings provide mechanistic support that SCFAs from periodontal pathogens stimulate KSHV replicat

256 The SCFA-induced reduction in body weight and stimulation of

257 the proportions and differences between the SCFA were calculated.

258 Together, these results establish the SCFA-hexosamine template as a versatile platform for mod

259 Accordingly, mice deficient for the SCFA receptor FFAR2 mirrored microglia defects found und

260 ntermediacy of malonyl-ACP in generating the SCFA precursor in a strain expressing this mutant.

261 Luminal perfusion of the SCFA acetate or propionate increased DBS, enhanced by di

262 humans, increased colonic production of the SCFA propionate acutely reduces energy intake.

263 athways in the colon, the involvement of the SCFA receptor free fatty acid receptor (FFA)3, one of th

264 tive PCR revealed enriched expression of the SCFA receptors ffar2 (grp43) and ffar3 (gpr41) in GLP-1-

265 e total amount and the amount of each of the SCFA were measured, and the proportions and differences

266 In summary, the regulation of the SCFA-MCT1-HMGCS2 axis is disrupted in K8(-/-) colonocyte

267 ile very high intake of dietary fibre or the SCFA acetate protects against colitis.

268 These results suggest that the SCFA-FFA3 pathway has a novel anti-secretory function in

269 The SCFAs were mainly excreted via the lungs after oxidation

270 Treatment with streptomycin altered the SCFAs in the cecum, significantly decreasing the concent

271 The orthologs with higher potency for the SCFAs, human FFA2 and mouse FFA3, displayed high constit

272 he metabolic products of the microbiota, the SCFAs, showed that formate was present in the ileum but

273 to (13) CO2 , whereas less than 0.05% of the SCFAs were excreted into urine.

274 The (SCFA) concentration increased (p < 0.01) during the trea

275 of their mode of action revealed that these SCFAs function as both activators of p42/p44 mitogen-act

276 In addition, all three SCFA mixtures increased fasting and postprandial plasma

277 All three SCFA mixtures increased fasting fat oxidation (P < 0.01)

278 Thus, gut microbiota acting through SCFAs are important determinants of enteric 5-HT product

279 Thus, SCFA production may be one mechanism by which microbiota

280 Thus, SCFAs, when systemically administered at levels higher t

281 ny promoter constructs following exposure to SCFAs.

282 table in NIH/3T3 cells following exposure to SCFAs.

283 To co-ordinate their response to SCFAs, L. pneumophila utilizes the LetA/LetS two-compone

284 e it mediates renin secretion in response to SCFAs.

285 03) and exhibited a trend for elevated total SCFA content (P < 0.06).

286 Total SCFAs increased in all colonic vessels with a rise in th

287 hanges in stool acetate (P = 0.02) and total SCFAs (P = 0.05) were higher in the WG group than in the

288 la OTU with equally high production of total SCFAs with propionate as the major product.

289 The mRNA and/or protein expression of two SCFA receptors, GPR41 and GPR43, in CF and non-CF bronch

290 tilized by gut microbes to produce these two SCFA from dietary carbohydrates and from amino acids res

291 Unexpectedly, SCFA contributions were elevated in both endocardium and

292 As) influence gut physiological function via SCFA receptors and transporters.

293 interactions in YAMC and Caco-2 cells where SCFAs synergistically enhance basal and ligand-induced e

294 l epithelia cells (IECs), we studied whether SCFAs modulate IEC hsp expression.

295 We tested whether SCFAs contribute to poor TB control in a longitudinal co

296 went four investigational days, during which SCFA mixtures (200 mmol/L) high in either acetate (HA),

297 erstanding the molecular mechanisms by which SCFAs beneficially affect physiological functions such a

298 d EKLF, and may be a mechanism through which SCFAs induce embryonic/fetal globin gene promoters durin

299 Treatment with SCFAs ameliorated EAE and reduced axonal damage via long

300 hormones while exposed to certain xenobiotic SCFAs.